Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

BACKGROUND: Bevacizumab provides clinical benefit in multiple solid tumours, but is associated with some increase in bleeding risk. Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of concurrent bevacizumab and TA in three large...

Descripción completa

Detalles Bibliográficos
Autores principales: Leighl, N B, Bennouna, J, Yi, J, Moore, N, Hambleton, J, Hurwitz, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049570/
https://www.ncbi.nlm.nih.gov/pubmed/21245868
http://dx.doi.org/10.1038/sj.bjc.6606074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049570/
https://www.ncbi.nlm.nih.gov/pubmed/21245868
http://dx.doi.org/10.1038/sj.bjc.6606074

Ejemplares similares